KAV13203
Anti-MPXV E8L Human IgM Antibody
Colorimetric
Plasma, Serum
Quantitative
93.75 - 6,000 ng/mL
22.1 ng/mL
CV<15%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Immunogenicity of monkeypox virus surface proteins and cross-reactive antibody responses in vaccinated and infected individuals: implications for vaccine and therapeutic development., PMID:39994775
A penta-component mpox mRNA vaccine induces protective immunity in nonhuman primates., PMID:39639037
Computational identification of monkeypox virus epitopes to generate a novel vaccine antigen against Mpox., PMID:39471737
Mpox global health emergency: Insights into the virus, immune responses, and advancements in vaccines PART II: Insights into the advancements in vaccines., PMID:39417768
Systematic evaluation of the induction of efficient neutralizing antibodies by recombinant multicomponent subunit vaccines against monkeypox virus., PMID:39321566
Discordant performance of mpox serological assays., PMID:39127186
In silico development of a novel anti-mutation, multi-epitope mRNA vaccine against MPXV variants of emerging lineage and sub-lineages by using immunoinformatics approaches., PMID:38450722
Supervised screening of Tecovirimat-like compounds as potential inhibitors for the monkeypox virus E8L protein., PMID:37561169
Immunogenic proteins and potential delivery platforms for mpox virus vaccine development: A rapid review., PMID:37353117
Rational development of multicomponent mRNA vaccine candidates against mpox., PMID:36947428
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
